OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 16,300 Shares

Key Points

• Director David Pelizzon sold 16,300 OrthoPediatrics shares at an average price of $24.74, generating $403,262. He continues to own 6.88 million shares, with the sale reducing his ownership by 0.24%.
• OrthoPediatrics recently exceeded quarterly expectations, reporting an adjusted loss of $0.26 per share versus the $0.30 consensus estimate and revenue of $70.51 million, ahead of the $68.21 million forecast.
• Analyst sentiment remains positive, with nine Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $26.44. The stock was recently trading at $24.03.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 16,300 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $24.74, for a total transaction of $403,262.00. Following the sale, the director directly owned 6,881,464 shares of the company's stock, valued at approximately $170,247,419.36. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

OrthoPediatrics Price Performance

OrthoPediatrics stock traded down $0.47 during mid-day trading on Wednesday, hitting $24.03. The company's stock had a trading volume of 169,608 shares, compared to its average volume of 171,545. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $627.42 million, a P/E ratio of -14.30 and a beta of 0.98. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The stock's fifty day moving average price is $21.11 and its two-hundred day moving average price is $18.53.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Research analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on KIDS shares. BTIG Research raised their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Piper Sandler reiterated an "overweight" rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings raised OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Finally, TD Cowen restated a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $26.44.

Institutional Trading of OrthoPediatrics

A number of institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after acquiring an additional 645 shares in the last quarter. Millennium Management LLC raised its holdings in shares of OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock valued at $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock valued at $4,937,000 after purchasing an additional 106,041 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of OrthoPediatrics in the 1st quarter valued at $389,000. Finally, American Century Companies Inc. boosted its holdings in OrthoPediatrics by 12.5% in the second quarter. American Century Companies Inc. now owns 34,486 shares of the company's stock worth $741,000 after purchasing an additional 3,828 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source